Zu den Inhalten springen

Tumorzentrum Freiburg - CCCF

Prof. Dr. med. Michael Lübbert

Contact:

Clinic for Internal Medicine I
Hematology, Oncology and stem cell transplantation
Hugstetter Straße 55
79106 Freiburg
Tel. (+49) 0761-270 35340
Fax (+49) 0761-270 36970
monika.falahen@uniklinik-freiburg.de

Current Positions:

Adjunct professor, Medical Center - University of Freiburg

Research Focus:

Characterization of epigenetic modifications with hematologic diseases and development of therapeutics (demethylating agents) for elder patients suffering from pre-leukemia or myeloid leukemia
Isolation and characterization of primitive human hematopoietic progenitor cells aimed to improve the autologous transplantation.

CRC 992: principal investigator project C04 - Modelling hypomethylating therapy for monosomal cytogenetic subgroups of acute myeloid leukemia.

SPP 1463: lead of project - Combined epigenetic therapy of AML: in vitro and translational studies of induction of gene expression and DNA hypomethylation

DKTK Research Platform Drug Development:

  • LSD1 inhibitors as new anticancer agents

DKTK Research Topics:

  • Oncogenic Mechanism, Topic Epigenetics:
    LACID: LSD1 as anticancer target in the clinic (TRANSATRA) and in drug discovery
  • Molecular Diganostics, Topic Development and Validation of Biomarkers:
    Resistance to azanucleoside DNA-hypomethylating agents (HMAs) and development of a methylation signature predictive for response to standard chemotherapy in older AML patients

Working Group Members DKTK:

Gabriele Greve           
Gregor Klaus   
Ruhtraud Ziegler       


Website:
http://www.uniklinik-freiburg.de/medizin1/behandlung/team-kontakt/oberaerzteinnen/prof-dr-michael-luebbert.html

Selected Publications:

Blum S, Greve G, Lübbert M. Innovative strategies for adverse karyotype acute myeloid leukemia: Current Opinion in Hematology. Januar 2017;1.

Schiffmann I, Greve G, Jung M, Lübbert M. Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics. 15. November 2016;00–00. 

Morera L, Lübbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clinical Epigenetics [Internet]. Dezember 2016 [zitiert 31. Mai 2016];8(1). Verfügbar unter: clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-016-0223-4

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na I-K, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. Oktober 2015;29(10):2062–8. 

Münch C, Dragoi D, Frey A-V, Thurig K, Lübbert M, Wäsch R, Bogatyreva L, Hauschke D, Lassmann S, Werner M, May AM. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leukemia Research [Internet]. Januar 2015 [zitiert 18. März 2015]; Verfügbar unter: linkinghub.elsevier.com/retrieve/pii/S0145212615000247

Meidhof S, Brabletz S, Lehmann W, Preca B-T, Mock K, Ruh M, Schuler J, Berthold M, Weber A, Burk U, Lubbert M, Puhr M, Culig Z, Wellner U, Keck T, Bronsert P, Kusters S, Hopt UT, Stemmler MP, Brabletz T. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Molecular Medicine [Internet]. 14. April 2015 [zitiert 20. April 2015]; Verfügbar unter: embomolmed.embopress.org/cgi/doi/10.15252/emmm.201404396 

Greve G, Schiffmann I, Pfeifer D, Pantic M, Schüler J, Lübbert M. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer [Internet]. Dezember 2015 [zitiert 7. Januar 2016];15(1). Verfügbar unter: www.biomedcentral.com/1471-2407/15/947

May AM, Frey A-V, Bogatyreva L, Benkisser-Petersen M, Hauschke D, Lübbert M, Wäsch R, Werner M, Hasskarl J, Lassmann S. ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes. Histochemistry and Cell Biology. 30. November 2013;141(4):431–40.

Blagitko-Dorfs N, Jiang Y, Duque-Afonso J, Hiller J, Yalcin A, Greve G, Abdelkarim M, Hackanson B, Lübbert M. Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat. PLoS One. 2013 Oct 8.

Solari L, Bauer T, Dicker F, Haferlach C, Grießhammer M, Schnittger S, Becker H, Lübbert M. A Novel Recurrent AML1-ETO fusion: Tight in vivo Association with BCR-ABL1. Leukemia. 2013 June 27: 1397-400.

Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, Plass C, Lübbert M., Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia., Leuk Res. 2013 Feb;37:190-6.

Duque-Afonso J, Berg T, Heidenreich O, Lübbert M.  The HDAC class I specific inhibitor Entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO.  Oncogene  30:3062-72, 2011

Lübbert M, Suciu S, Baila L, Rüter B, Platzbecker U, Giagounidis A, et al. Low-dose decitabine vs. Best Supportive Care in elderly patients with intermediate- or high-risk MDS ineligible for intensive chemotherapy: final results of the randomized phase III study of the EORTC Leukemia Group and the German MDS Study Group.  J. Clin. Oncol.  29:2889-96, 2011

Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lübbert M. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on gene expression in acute myeloid leukemia cells. Leukemia 23:1019-28, 2009

Daskalakis, M., Nguyen, T.T., Nguyen, C., Guldberg, P., Köhler, G., Wijermans, P., Jones, P.A., Lübbert, M. Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine treatment.  Blood 100:2957-2964, 2002

-- Logo: © dkfz.de

Prof. Dr. Christoph Peters
Tumorzentrum Freiburg CCCF
Phone: +49-761-270-71500
Hugstetter Str. 49
79106 Freiburg

and

Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Str. 17
79104 Freiburg
Phone: +49-761-203-9600/9601
christoph.peters@mol-med.uni-freiburg.de​​

Dr. Anja Hernández
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
++49 (0)761 270 22810
anja.hernandez@dkfz-heidelberg.de

Dr. Anna Dost
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
+49 (0)761 270 77121
a.dost@dkfz-heidelberg.de